{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:57:06Z","timestamp":1793159826891,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","award":["20180302"],"award-info":[{"award-number":["20180302"]}],"id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sarcopenia is a muscle disease characterized by reduction of muscle strength and muscle mass. In RA, 25.9 to 43.3% of the patients present sarcopenia. The loss of muscle mass observed in RA patients occurs either by activation of catabolic pathways or by inhibition of anabolic pathways. Despite having a list of drugs capable of treating RA inflammation, their effect on muscle is unclear. Our objective was to evaluate the tofacitinib effect on the muscle mass of collagen-induced arthritis (CIA) mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      CIA was induced in male DBA\/1J mice by subcutaneous injection of Type 2 Collagen plus Freund Adjuvant. Animals were randomized into 3 groups: CIA\u2009+\u2009tofacitinib; CIA\u2009+\u2009vehicle; and healthy controls. Treatment was administered twice a day, between days 18 and 45 after induction. Clinical score, edema, and body weight were evaluated during the experimental period. After euthanasia, tibiotarsal joints were collected for assessment of disease histopathological score, and tibialis anterior (TA) and gastrocnemius (GA) muscles were weighed to assess muscle mass. Muscle atrophy was evaluated by measurement of TA myofiber cross-sectional area (CSA). Protein expression was evaluated by western blot using GA homogenates. Serum inflammatory markers were evaluated by ELISA. Statistical analysis included ANOVA followed by Tukey\u2019s or with Kruskal-Wallis. The statistical difference was assumed for\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tofacitinib treatment decreased arthritis severity by reducing clinical score, and hind paw edema in comparison with the vehicle group. Tofacitinib showed weight gain, higher TA and GA weights, and increased CSA compared to the vehicle group. On day 45, Tofacitinib presented increased muscle strength compared to the vehicle group, however, no difference was found in muscle fatigue. Pax7 expression was unchanged, while MyoD expression showed an increasing trend, and myogenin expression was significantly increased in Tofacitinib compared to vehicle and control groups. The treatment didn\u2019t modify Murf-1 expression. Tofacitinib mice showed decreased serum levels of TNF and increased IL-6 serum levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tofacitinib attenuated muscle loss in arthritic mice, increased muscle weight and muscle CSA. Activation of satellite cell regeneration, based on the increased expression of myogenin, is a potential mechanism involved in tofacitinib action against muscle loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-024-00416-5","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T02:03:51Z","timestamp":1731463431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment with tofacitinib attenuates muscle loss through myogenin activation in the collagen-induced arthritis"],"prefix":"10.1186","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-0471","authenticated-orcid":false,"given":"Thales Hein","family":"da Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara Jonson","family":"Bartikoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Cavalheiro","family":"do Esp\u00edrito Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian","family":"Farinon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana Miranda","family":"de Souza Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Ternus","family":"Ped\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lu\u00edsa","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"Karnopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Peterson","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Chapacais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andressa","family":"di Domenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Loch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Machado","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"416_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrrheum.2014.121","volume":"10","author":"G Kerekes","year":"2014","unstructured":"Kerekes G, Nurmohamed MT, Gonz\u00e1lez-Gay MA, Seres I, Paragh G, Kardos Z, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014;10:691\u201396.","journal-title":"Nat Rev Rheumatol"},{"key":"416_CR2","first-page":"179","volume":"74","author":"W Gawrysiak","year":"2017","unstructured":"Gawrysiak W, Skrypnik K, Suliburska J, Skrypnik D, Bogda\u0144ski P. [Cardiac complications in rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis]. Przegl Lek. 2017;74:179\u201382.","journal-title":"Przegl Lek"},{"key":"416_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in older people. Age Ageing. 2010;39:412.","journal-title":"Age Ageing"},{"key":"416_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr.23775","volume":"71","author":"BY Hanaoka","year":"2019","unstructured":"Hanaoka BY, Ithurburn MP, Rigsbee CA, Bridges SL, Moellering DR, Gower B, et al. Chronic inflammation in RA: mediator of skeletal muscle pathology and physical impairment. Arthritis Care Res (Hoboken). 2019;71:173.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"416_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ebiom.2017.07.023","volume":"23","author":"T Yamada","year":"2017","unstructured":"Yamada T, Steinz MM, Kenne E, Lanner JT. Muscle weakness in rheumatoid arthritis: the role of Ca2 + and free radical signaling. EBioMedicine. 2017;23:12\u201319.","journal-title":"EBioMedicine"},{"key":"416_CR6","first-page":"172","volume":"58","author":"SY Chang","year":"2022","unstructured":"Chang SY, Han BD, do Han K, Park HJ, Kang S. Relation between handgrip strength and quality of life in patients with arthritis in Korea: the Korea National Health and Nutrition Examination Survey, 2015\u20132018. Medicina (Lithuania). 2022;58:172.","journal-title":"Medicina (Lithuania)"},{"key":"416_CR7","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/jbmr.4021","volume":"35","author":"J Li","year":"2020","unstructured":"Li J, Yi X, Yao Z, Chakkalakal JV, Xing L, Boyce BF. TNF receptor-associated factor 6 mediates TNF\u03b1-induced skeletal muscle atrophy in mice during aging. J Bone Miner Res. 2020;35:1535.","journal-title":"J Bone Miner Res"},{"key":"416_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0092-8674(00)00066-0","volume":"102","author":"P Seale","year":"2000","unstructured":"Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell. 2000;102:777\u201386.","journal-title":"Cell"},{"key":"416_CR9","doi-asserted-by":"publisher","first-page":"16474","DOI":"10.1073\/pnas.1307680110","volume":"110","author":"J von Maltzahn","year":"2013","unstructured":"von Maltzahn J, Jones AE, Parks RJ, Rudnicki MA. Pax7 is critical for the normal function of satellite cells in adult skeletal muscle. Proc Natl Acad Sci U S A. 2013;110:16474\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"416_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ydbio.2004.08.015","volume":"275","author":"HC Olguin","year":"2004","unstructured":"Olguin HC, Olwin BB. Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev Biol. 2004;275:375\u201388.","journal-title":"Dev Biol"},{"key":"416_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.semcdb.2017.11.010","volume":"72","author":"JM Hern\u00e1ndez-Hern\u00e1ndez","year":"2017","unstructured":"Hern\u00e1ndez-Hern\u00e1ndez JM, Garc\u00eda-Gonz\u00e1lez EG, Brun CE, Rudnicki MA. The myogenic regulatory factors, determinants of muscle development, cell identity and regeneration. Semin Cell Dev Biol. 2017;72:10\u201318.","journal-title":"Semin Cell Dev Biol"},{"key":"416_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/BOR.0000000000000792","volume":"33","author":"V Reddy","year":"2021","unstructured":"Reddy V, Cohen S. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment. Curr Opin Rheumatol. 2021;33:300\u201306.","journal-title":"Curr Opin Rheumatol"},{"key":"416_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58:953.","journal-title":"Rheumatology (Oxford)"},{"key":"416_CR14","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, et al. The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.","journal-title":"Int Immunopharmacol"},{"key":"416_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fphys.2019.00500","volume":"10","author":"V Moresi","year":"2019","unstructured":"Moresi V, Adamo S, Berghella L. The JAK\/STAT pathway in skeletal muscle pathophysiology. Front Physiol. 2019;10:500.","journal-title":"Front Physiol"},{"key":"416_CR16","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","volume":"303","author":"A Bonetto","year":"2012","unstructured":"Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, et al. JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012;303:E410.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"416_CR17","first-page":"e23282","volume":"2","author":"Y-N Jang","year":"2013","unstructured":"Jang Y-N, Baik EJ. JAK-STAT pathway and myogenic differentiation. Jakstat. 2013;2:e23282.","journal-title":"Jakstat"},{"key":"416_CR18","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1113\/JP281220","volume":"599","author":"AB Addinsall","year":"2021","unstructured":"Addinsall AB, Cacciani N, Akkad H, Salah H, Tchkonia T, Kirkland JL, et al. JAK\/STAT inhibition augments soleus muscle function in a rat model of critical illness myopathy via regulation of complement C3\/3R. J Physiol. 2021;599:2869\u201386.","journal-title":"J Physiol"},{"key":"416_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-021-02679-5","volume":"24","author":"TR Hein","year":"2022","unstructured":"Hein TR, Peterson L, Bartikoski BJ, Portes J, Esp\u00edrito Santo RC, Xavier RM. The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis. Arthritis Res Ther. 2022;24:1\u201314.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"416_CR20","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand DD, Latham KA, Rosloniec EF.Collagen-induced arthritis. Nat Protocols. 2007;2(5):1269\u201375.","journal-title":"Nat Protocols"},{"key":"416_CR21","doi-asserted-by":"crossref","unstructured":"Deacon RMJ. Measuring the strength of mice. J Vis Exp. 2013;e2610.","DOI":"10.3791\/2610"},{"key":"416_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jcsm.12280","volume":"9","author":"PVG Alabarse","year":"2018","unstructured":"Alabarse PVG, Lora PS, Silva JMS, Santo RCE, Freitas EC, de Oliveira MS, et al. Collagen-induced arthritis as an animal model of rheumatoid cachexia. J Cachexia Sarcopenia Muscle. 2018;9:603.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"416_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-1-0716-0884-5_17","volume":"2201","author":"G Campana","year":"2021","unstructured":"Campana G, Rimondini R. Mechanical nociception in mice and rats: measurement with automated von frey equipment. Methods Mol Biol. 2021;2201:195\u201398.","journal-title":"Methods Mol Biol"},{"key":"416_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/art.20782","volume":"52","author":"M Brenner","year":"2005","unstructured":"Brenner M, Meng HC, Yarlett NC, Griffiths MM, Remmers EF, Wilder RL, et al. The non-major histocompatibility complex quantitative trait locus Cia10 contains a major arthritis gene and regulates disease severity, pannus formation, and joint damage. Arthritis Rheum. 2005;52:322\u201332.","journal-title":"Arthritis Rheum"},{"key":"416_CR25","first-page":"pdb","volume":"3","author":"AH Fischer","year":"2008","unstructured":"Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. Cold Spring Harb Protoc. 2008;3:pdb-rot4986.","journal-title":"Cold Spring Harb Protoc"},{"key":"416_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-4939-6990-6_9","volume":"1606","author":"B Kim","year":"2017","unstructured":"Kim B. Western blot techniques. Methods Mol Biol. 2017;1606:133\u201339.","journal-title":"Methods Mol Biol"},{"key":"416_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s13539-013-0102-1","volume":"4","author":"LI Filippin","year":"2013","unstructured":"Filippin LI, Teixeira VN, Viacava PR, Lora PS, Xavier LL, Xavier RM. Temporal development of muscle atrophy in murine model of arthritis is related to disease severity. J Cachexia Sarcopenia Muscle. 2013;4:231\u201338.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"416_CR28","doi-asserted-by":"crossref","unstructured":"Cavalheiro R, Hein T, Xavier RM. The effect of pharmacological treatment on rheumatoid arthritis related sarcopenia: an integrative review. Curr Rheumatol Res. 2021;2.","DOI":"10.46439\/rheumatology.2.011"},{"key":"416_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42358-022-00249-0","volume":"62","author":"MPGUES de Souza","year":"2022","unstructured":"de Souza MPGUES, Guimar\u00e3es NS, de Resende Guimar\u00e3es MFB, de Souza VA, Kakehasi AM. Effect of biological disease-modifying antirheumatic drugs on body composition in patients with rheumatoid arthritis: a systematic review and meta-analysis. Adv Rheumatol. 2022;62:1\u201310.","journal-title":"Adv Rheumatol"},{"key":"416_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865.","journal-title":"Ann Rheum Dis"},{"key":"416_CR31","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/nm.3655","volume":"20","author":"FD Price","year":"2014","unstructured":"Price FD, Von Maltzahn J, Florian Bentzinger C, Dumont NA, Yin H, Chang NC, et al. Inhibition of JAK\/STAT signaling stimulates adult satellite cell function HHS Public Access Author manuscript. Nat Med. 2014;20:1174\u201381.","journal-title":"Nat Med"},{"key":"416_CR32","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.41602","volume":"73","author":"JJ Paik","year":"2021","unstructured":"Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol. 2021;73:858\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"416_CR33","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/nm.3656","volume":"20","author":"MT Tierney","year":"2014","unstructured":"Tierney MT, Aydogdu T, Sala D, Malecova B, Gatto S, Puri PL, et al. STAT3 signaling controls satellite cell expansion and skeletal muscle repair. Nat Med. 2014;20:1182\u201386.","journal-title":"Nat Med"},{"key":"416_CR34","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/nm.3655","volume":"20","author":"FD Price","year":"2014","unstructured":"Price FD, von Maltzahn J, Bentzinger CF, Dumont NA, Yin H, Chang NC, et al. Inhibition of JAK\/STAT signaling stimulates adult satellite cell function. Nat Med. 2014;20:1174.","journal-title":"Nat Med"},{"key":"416_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nm.3465","volume":"20","author":"JD Bernet","year":"2014","unstructured":"Bernet JD, Doles JD, Hall JK, Kelly Tanaka K, Carter TA, Olwin BB. P38 MAPK signaling underlies a cell autonomous loss of stem cell self-renewal in aged skeletal muscle. Nat Med. 2014;20:265.","journal-title":"Nat Med"},{"key":"416_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nm.3464","volume":"20","author":"BD Cosgrove","year":"2014","unstructured":"Cosgrove BD, Gilbert PM, Porpiglia E, Mourkioti F, Lee SP, Corbel SY, et al. Rejuvenation of the muscle stem cell population restores strength to injured aged muscles. Nat Med. 2014;20:255\u201364.","journal-title":"Nat Med"},{"key":"416_CR37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2152\/jmi.65.166","volume":"65","author":"M Chikugo","year":"2018","unstructured":"Chikugo M, Sebe M, Tsutsumi R, Iuchi M, Kishi J, Kuroda M, et al. Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism. J Med Invest. 2018;65:166\u201370.","journal-title":"J Med Invest"},{"key":"416_CR38","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","volume":"60","author":"Z Yu","year":"2021","unstructured":"Yu Z, Wang L, Quan M, Zhang T, Song H. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology. 2021;60:1700\u201307.","journal-title":"Rheumatology"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00416-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-024-00416-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00416-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T02:03:56Z","timestamp":1731463436000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-024-00416-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1186\/s42358-024-00416-5","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of the Hospital de Cl\u00ednicas de Porto Alegre (protocol number 18-0302).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"Thales Hein da Rosa, B\u00e1rbara Bartikoski, Rafaela Cavalheiro do Esp\u00edrito Santo, Mirian Farinon, Jordana Miranda de Souza Silva, Renata Ternus Pedo, Maria Lu\u00edsa Gasparini, Tha\u00eds Karnopp, Leonardo Santos, Gustavo Chapacais, Andressa Di Domenico, Sofia Loch: None declared, Ricardo Xavier Grant\/research support from Pfizer Grant 60289911.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"85"}}